Company
We started with a simple question: what happens to the people we cannot see between visits?
MbeleMed, Inc. is building the infrastructure to help healthcare organizations identify, monitor, review, and act on silent cardiac risk, especially in populations traditional pathways may reach late.
Philip Butler, Founder & CEO
What MbeleMed is building
MbeleMed connects:
- population prioritization;
- accessible monitoring;
- physician review;
- follow-up;
- evidence and learning.
MbeleMed does not manufacture or own monitoring devices.
Founder & CEO
Philip Butler
Philip Butler is Founder & CEO of MbeleMed.
Before founding the company, Philip worked across value-based care investing, healthcare company building, and strategic finance, and served on the board of a leading remote cardiac monitoring company.
He earned a BA in Economics and Political Science from Morehouse College and an MBA from The Wharton School of the University of Pennsylvania, with concentrations in Finance and Real Estate.
His current work focuses on population cardiovascular risk stratification, arrhythmia screening, maternal and postpartum cardiovascular health, older-adult cardiovascular risk, and the use of longitudinal clinical and physiologic data to improve targeted monitoring.
Why MbeleMed exists
The problem became personal before it became professional.
An immediate family member's atrial fibrillation went undetected until it was discovered during a sleep study, despite ongoing contact with the healthcare system.
That experience shaped a simple belief:
Finding a problem is only the beginning. The right person has to be reached, the finding has to be credible, and someone has to know what happens next.
Advisors
Khai Edouard
Advisor
Corinne Charity
Advisor
Craig Harper
Advisor
Current focus
Start with high-risk seniors. Build for a much broader future.
MbeleMed's initial commercial focus is high-risk senior populations and the organizations responsible for their care and outcomes.
The underlying infrastructure is designed to support broader populations and additional research questions over time.
Emerging maternal and postpartum applications remain separately labeled as research or pilot-stage work.
Recognition
2026 BioNTX Rising Star
Top 12 Finalist, WT Innovation World Cup USA 2026
Operating principles
Clinicians stay in command
Technology should make clinical teams more informed and more effective, never replace qualified judgment.
Find the right people
Better targeting matters more than indiscriminate screening.
Tell the truth about maturity
Published evidence, internal analysis, demonstrated workflow, pilot work, research-stage methods, and roadmap items stay distinct.
Make the pathway practical
Monitoring only matters if people can actually access it and someone knows what to do with the result.
Keep responsibility clear
Devices, interpretation, clinical decisions, follow-up, claims, and research rights should never be blurred.
Learn before scaling
Start with a defined program, measure it honestly, and expand when the evidence supports expansion.
